Sarepta Therapeutics Inc (SRPT)

Jan 20, 2025

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Insider Monkey

Jan 20, 2025

Jan 19, 2025

Smith Salley Wealth Management Invests $889,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Jan 19, 2025

Jan 18, 2025

Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says - MSN

Jan 18, 2025

Jan 18, 2025

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat

Jan 18, 2025

Jan 17, 2025

Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI + - Seeking Alpha

Jan 17, 2025

Jan 17, 2025

FY2024 Earnings Forecast for SRPT Issued By HC Wainwright - MarketBeat

Jan 17, 2025

Jan 17, 2025

Stock Market Movers Today • Top Gainers & Losers - Benzinga

Jan 17, 2025

Jan 16, 2025

Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely (NASDAQ:SRPT) - Seeking Alpha

Jan 16, 2025

Jan 16, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Given "Sell" Rating at HC Wainwright - MarketBeat

Jan 16, 2025

Jan 16, 2025

HC Wainwright Issues Optimistic Forecast for SRPT Earnings - MarketBeat

Jan 16, 2025

Jan 16, 2025

Sarepta preliminary Q4 revenue beats, but full year just misses - MSN

Jan 16, 2025

Jan 15, 2025

What 14 Analyst Ratings Have To Say About Sarepta Therapeutics - Benzinga

Jan 15, 2025

Jan 15, 2025

J&J files a potential blockbuster; Lykos shakes up its board - BioPharma Dive

Jan 15, 2025

Jan 15, 2025

HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat

Jan 15, 2025

Jan 15, 2025

Harbor Capital Advisors Inc. Acquires 427 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Jan 15, 2025

Jan 14, 2025

Sarepta, Biogen drugs with accelerated approval under fire in FDA report - Seeking Alpha

Jan 14, 2025

Jan 14, 2025

Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says | Company Business News - Mint

Jan 14, 2025

Jan 14, 2025

Sarepta Bullish After Another Big Beat For Elevidys - News & Insights

Jan 14, 2025

Jan 14, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Jan 14, 2025

Jan 14, 2025

U.S, Europe And GCC Antisense Oligonucleotide (ASO) - openPR

Jan 14, 2025

Jan 14, 2025

Sarepta Previews Q4 Findings, Touts Elevidys Earnings Beat - BioSpace

Jan 14, 2025

Jan 13, 2025

Neuromuscular Disease Therapeutics Market to Grow by USD 13.73 Billion from 2025-2029, Driven by Novel Approvals and AI-Driven Market TransformationTechnavio - The Malaysian Reserve

Jan 13, 2025

Jan 13, 2025

Sarepta exceeds revenue forecasts, maintains 2025 guidance - Investing.com India

Jan 13, 2025

Jan 13, 2025

Sarepta Therapeutics Tops 2024 Net Product Revenue Guidance - MarketWatch

Jan 13, 2025

Jan 13, 2025

Sarepta Therapeutics (SRPT) Reports Preliminary Fourth Quarter and Full-Year 2024 Net Product Revenue - StreetInsider.com

Jan 13, 2025

Jan 13, 2025

Sarepta Therapeutics Smashes Revenue Targets as ELEVIDYS Sales Surge 112% in Q4 2024 - StockTitan

Jan 13, 2025

Jan 13, 2025

Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy - Business Wire

Jan 13, 2025

Jan 10, 2025

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Nordea Investment Management AB - MarketBeat

Jan 10, 2025

Jan 09, 2025

Zacks Research Issues Pessimistic Forecast for SRPT Earnings - MarketBeat

Jan 09, 2025

Jan 09, 2025

Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock poised for growth - Investing.com Canada

Jan 09, 2025

Jan 08, 2025

Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED) - Benzinga

Jan 08, 2025

Jan 08, 2025

Nippon Shinyaku Hit With Royalty Tab After $115 Million Verdict - Bloomberg Law

Jan 08, 2025

Jan 08, 2025

SRPT February 28th Options Begin Trading - Nasdaq

Jan 08, 2025

Jan 08, 2025

SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell? - MSN

Jan 08, 2025

Jan 07, 2025

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference - Benzinga

Jan 07, 2025

Jan 06, 2025

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire

Jan 06, 2025

Jan 01, 2025

Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Target Price at $178.71 - MarketBeat

Jan 01, 2025

Dec 31, 2024

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Dec 31, 2024

Dec 31, 2024

LABU, NTRA, INCY, SRPT: Large Inflows Detected at ETF - Nasdaq

Dec 31, 2024

Dec 31, 2024

Sarepta Therapeutics Grants 10,660 RSUs to New Employees in Strategic Talent Acquisition Move - StockTitan

Dec 31, 2024

Dec 29, 2024

Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey

Dec 29, 2024

Dec 28, 2024

10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey

Dec 28, 2024

Dec 26, 2024

Duchenne Muscular Dystrophy Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeuti - Barchart

Dec 26, 2024

Dec 26, 2024

Exploring High Growth Tech Stocks in the US December 2024 - Simply Wall St

Dec 26, 2024

Dec 25, 2024

Page 4 | SAREPTA THERAPEUTICS, INC Trade Ideas — BIVA:SRPT - TradingView

Dec 25, 2024

Dec 25, 2024

SAREPTA THERAPEUTICS, INC Trade Ideas — BIVA:SRPT - TradingView

Dec 25, 2024

Dec 24, 2024

Principal Financial Group Inc. Sells 95,974 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 24, 2024

Dec 23, 2024

Is Sarepta Therapeutics, Inc. (SRPT) the Best Performing Biotech Stock in 2024? - Insider Monkey

Dec 23, 2024